Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(2):283–286. doi: 10.1038/bjc.1997.46

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

C Bain 1, Y Merrouche 1, I Puisieux 1, J Y Blay 1, S Negrier 1, V Bonadona 1, C Lasset 1, F Lanier 1, A Duc 1, L Gebuhrer 1, T Philip 1, M C Favrot 1
PMCID: PMC2063266  PMID: 9010039

Abstract

HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.

Full text

PDF
286

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  2. Bain C., Merrouche Y., Puisieux I., Duc A., Colombo M. P., Favrot M. B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer. 1996 Sep 17;67(6):769–776. doi: 10.1002/(SICI)1097-0215(19960917)67:6<769::AID-IJC4>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  3. Bernhard H., Karbach J., Wölfel T., Busch P., Störkel S., Stöckle M., Wölfel C., Seliger B., Huber C., Meyer zum Büschenfelde K. H. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer. 1994 Dec 15;59(6):837–842. doi: 10.1002/ijc.2910590621. [DOI] [PubMed] [Google Scholar]
  4. Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
  5. Dellon A. L., Rogentine G. N., Jr, chretien P. B. Prolonged survival in bronchogenic carcinoma associated with HL-A antigens W-19 and HL-A5: a preliminary report. J Natl Cancer Inst. 1975 Jun;54(6):1283–1286. doi: 10.1093/jnci/54.6.1283. [DOI] [PubMed] [Google Scholar]
  6. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O'Shea J. J., Kudoh S., Klein E. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993 Dec 1;53(23):5613–5616. [PubMed] [Google Scholar]
  7. Kantor A. F., McLaughlin J. K., Blattner W. A., Bach F. H., Blot W. J., Schuman L. M., Fraumeni J. F., Jr HLA antigens in renal cell carcinoma. Cancer Res. 1983 May;43(5):2330–2333. [PubMed] [Google Scholar]
  8. LILLY F., BOYSE E. A., OLD L. J. GENETIC BASIS OF SUSCEPTIBILITY TO VIRAL LEUKAEMOGENESIS. Lancet. 1964 Dec 5;2(7371):1207–1209. doi: 10.1016/s0140-6736(64)91043-8. [DOI] [PubMed] [Google Scholar]
  9. Marincola F. M., Shamamian P., Rivoltini L., Salgaller M., Cormier J., Restifo N. P., Simonis T. B., Venzon D., White D. E., Parkinson D. R. HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):242–252. doi: 10.1097/00002371-199511000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Merrouche Y., Negrier S., Bain C., Combaret V., Mercatello A., Coronel B., Moskovtchenko J. F., Tolstoshev P., Moen R., Philip T. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol. 1995 Feb;13(2):410–418. doi: 10.1200/JCO.1995.13.2.410. [DOI] [PubMed] [Google Scholar]
  11. Negrier S., Philip T., Stoter G., Fossa S. D., Janssen S., Iacone A., Cleton F. S., Eremin O., Israel L., Jasmin C. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol. 1989;25 (Suppl 3):S21–S28. [PubMed] [Google Scholar]
  12. Oliver R. T., Pillai A., Klouda P. T., Lawler S. D. HLA linked resistance factors and survival in acute myelogenous leukemia. Cancer. 1977 Jun;39(6):2337–2341. doi: 10.1002/1097-0142(197706)39:6<2337::aid-cncr2820390603>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  13. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  14. Rubin J. T., Day R., Duquesnoy R., Simonis B., Adams S., Lee J., Lotze M. T. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol. 1995 Feb;2(1):1–6. [PubMed] [Google Scholar]
  15. Scheibenbogen C., Keilholz U., Mytilineos J., Suciu S., Manasterski M., Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res. 1994 Jun;4(3):191–194. doi: 10.1097/00008390-199406000-00008. [DOI] [PubMed] [Google Scholar]
  16. Schendel D. J., Gansbacher B., Oberneder R., Kriegmair M., Hofstetter A., Riethmüller G., Segurado O. G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol. 1993 Oct 15;151(8):4209–4220. [PubMed] [Google Scholar]
  17. Wang Q., Redovan C., Tubbs R., Olencki T., Klein E., Kudoh S., Finke J., Bukowski R. M. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer. 1995 Jun 9;61(6):780–785. doi: 10.1002/ijc.2910610607. [DOI] [PubMed] [Google Scholar]
  18. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES